Market closed
Harvard Bioscience/$HBIO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Harvard Bioscience
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Ticker
$HBIO
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
404
Website
HBIO Metrics
BasicAdvanced
$102M
Market cap
-
P/E ratio
-$0.33
EPS
1.31
Beta
-
Dividend rate
Price and volume
Market cap
$102M
Beta
1.31
52-week high
$5.56
52-week low
$1.99
Average daily volume
169K
Financial strength
Current ratio
2.057
Quick ratio
0.765
Long term debt to equity
63.043
Total debt to equity
70.289
Interest coverage (TTM)
-1.50%
Management effectiveness
Return on assets (TTM)
-2.19%
Return on equity (TTM)
-20.40%
Valuation
Price to revenue (TTM)
1.036
Price to book
1.56
Price to tangible book (TTM)
-22.89
Price to free cash flow (TTM)
633.117
Growth
Revenue change (TTM)
-13.15%
Earnings per share change (TTM)
314.71%
3-year revenue growth (CAGR)
-5.78%
3-year earnings per share growth (CAGR)
91.99%
What the Analysts think about HBIO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Harvard Bioscience stock.
HBIO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HBIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HBIO News
AllArticlesVideos
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
GlobeNewsWire·1 month ago
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Harvard Bioscience stock?
Harvard Bioscience (HBIO) has a market cap of $102M as of December 11, 2024.
What is the P/E ratio for Harvard Bioscience stock?
The price to earnings (P/E) ratio for Harvard Bioscience (HBIO) stock is 0 as of December 11, 2024.
Does Harvard Bioscience stock pay dividends?
No, Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders as of December 11, 2024.
When is the next Harvard Bioscience dividend payment date?
Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Harvard Bioscience?
Harvard Bioscience (HBIO) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.